199 related articles for article (PubMed ID: 19931195)
1. Pharmacogenetic profiling in the treatment of heart disease.
Dorn GW
Transl Res; 2009 Dec; 154(6):295-302. PubMed ID: 19931195
[TBL] [Abstract][Full Text] [Related]
2. [The clinical pharmacology of beta-adrenoblockers].
Sychev DA; Ramenskaia GV; Ignat'ev IV; Smirnikhina SA; Kazakov RE; Kukes VG
Klin Med (Mosk); 2006; 84(3):4-9. PubMed ID: 16758913
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of beta-blockers.
Shin J; Johnson JA
Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770
[TBL] [Abstract][Full Text] [Related]
4. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of cardiovascular pharmacogenetics.
Voora D; Ginsburg GS
J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
8. Beta-blocker pharmacogenetics in heart failure.
Shin J; Johnson JA
Heart Fail Rev; 2010 May; 15(3):187-96. PubMed ID: 18437562
[TBL] [Abstract][Full Text] [Related]
9. Chronic heart failure: beta-blockers and pharmacogenetics.
Azuma J; Nonen S
Eur J Clin Pharmacol; 2009 Jan; 65(1):3-17. PubMed ID: 18839161
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.
Vandel P; Talon JM; Haffen E; Sechter D
Curr Pharm Des; 2007; 13(2):241-50. PubMed ID: 17269931
[TBL] [Abstract][Full Text] [Related]
11. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.
Zoghi M; Kaya H; Çavuşoğlu Y; Aksakal E; Demir Ş; Yücel C; Mutlu H; Ergene O; Yılmaz MB;
Turk Kardiyol Dern Ars; 2016 Sep; 44(6):457-65. PubMed ID: 27665326
[TBL] [Abstract][Full Text] [Related]
12. [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
Wuttke H; Rau T; Eschenhagen T
Dtsch Med Wochenschr; 2004 Apr; 129(15):831-5. PubMed ID: 15054690
[No Abstract] [Full Text] [Related]
13. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.
Teh LK; Bertilsson L
Drug Metab Pharmacokinet; 2012; 27(1):55-67. PubMed ID: 22185816
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine pharmacogenetics: a comprehensive review.
Suwała J; Machowska M; Wiela-Hojeńska A
Pharmacogenomics; 2019 Jul; 20(11):829-845. PubMed ID: 31368838
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics and heart failure: a convergence with carvedilol.
Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
[No Abstract] [Full Text] [Related]
18. [Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport].
Allorge D; Loriot MA
Ann Biol Clin (Paris); 2004; 62(5):499-511. PubMed ID: 15355800
[TBL] [Abstract][Full Text] [Related]
19. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]